CannTrust Holdings halted all sales of cannabis products while Canada’s federal regulator inspects its Vaughan, Ontario manufacturing facility. The Ontario company received a “noncompliant” rating earlier this week by Health Canada for operating five unlicensed rooms.
That means the company’s 72,000 registered medical patients will have to look to other producers to fill their orders, likely worsening Canada’s supply crunch.
CannTrust also established a committee comprised of independent board members to investigate the matter.
Health Canada conducted an unannounced inspection at CannTrust’s facility in Pelham on June 17, days after being tipped off about unlicensed cultivation by a former employee. That resulted in “critical observations” and an overall noncompliant rating.
CannTrust has until next week to respond to the Health Canada’s report.
At that point the regulator will determine the compliance and enforcement action, with growing speculation that the company’s cultivation and sales licenses could be suspended.
The company was also found to have shipped some of the unlicensed medical marijuana overseas.
CannTrust shares trade as CTST on the New York Stock Exchange and as TRST on the Toronto Stock Exchange.
CannTrust Holdings 停止了大麻产品的所有销售，而加拿大联邦监管机构检查了其位于安大略省沃恩的生产设施。加拿大卫生部( Health Canada )本周早些时候对这家安大略公司进行了“违规”评级，原因是该公司经营着5间无证客房。
6月17日，加拿大卫生部( Health Canada )对 CannTrust 位于 Pelham 的工厂进行了一次未经宣布的检查，此前有几天，一名前雇员被告知未经许可的种植。这导致了“关键观察”和整体不符合评级。
CannTrust 的股票在纽约证券交易所交易为 CTST ，在多伦多证券交易所交易为 TRST 。